In ameloblastoma, the overexpression of SOX10, LRP5, and SLC6A3 may possibly be related to increased cell proliferation, local invasion, and high recurrence rates; as such therapeutic alternatives such as parthenolide and vorinostat may be employed as inhibitors of these genes. Here, LRP5 is linked to ameloblastoma.